the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title Study of ADCT-301 in Patients With Relapsed/Refractory Cluster of Differentiation 25(CD25)-Positive Acute Myeloid Leukemia (AML)
Official Title A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML)
Principal Investigator Stock, Wendy
Brief Summary This study evaluates ADCT-301 in patients with Acute Myeloid Leukemia (AML). Patients will participate in a dose-escalation phase (Part 1) and receive ADCT-301 every 3 weeks. In Part 2 of the study, patients will receive a recommended dose of ADCT-301 every 3 weeks.
Gender Both
Ages 18 Years
Enrollment 60
Accepts Healthy Volunteers No
Lead Sponsor ADC Therapeutics SARLIndustry
Study Design Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Study Phase Phase 1
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Acute Myeloid Leukemia
Detail for Health Professional (on
More clinical trials by this PI